AAM All Access Podcast - Dan Leonard interviews pharmaceutical industry veteran Bob Billings

Prescription for State Savings

State lawmakers can take meaningful action to lower brand prescription drug costs with the Prescription for State Savings. AAM outlines several solutions states could pursue.

Learn More
Featured AAM All Access Podcast: Bob Billings

Bob Billings, active in the pharmaceuticals industry for more than 25 years, speaks with AAM CEO Dan Leonard about the evolution of the generics industry. “We need innovation, and generics are where access and innovation intersect.”

Listen to Podcast
Congress Needs To Hear From You!

Lawmakers are actively considering prescription drug reforms included in the Build Back Better Act (H.R. 5376) that would undermine patient access to affordable FDA-approved generic and biosimilar medicines. Tell your Senator not to put these medicines at risk!

Take Action!
AAM Encourages Congress to Protect Patient Savings

Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. AAM strongly opposes negotiations in Medicare that would jeopardize these savings.

Learn More
Access! 2022

Access! brings together policymakers, influential speakers and industry leaders to shape the future of generics and biosimilars. Plan to join us February 14-16 in Orlando for the first time in person since 2019! 

Register Today
2021 U.S. Generic and Biosimilar Medicines Savings Report

Report reveals continued savings growth through lower-cost generic and biosimilar competition. The findings reinforce the outsized importance of the industry delivering lifesaving & health-managing medicines.

View Full Report
Patient Stories: Voices of Access

AAM's Voices of Access report features patients across the country who tell the impact of accessible generic and biosimilar medicines.

Meet the AAM Patients

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Jan 12, 2022 | Erica Klinger

Generics and Biosimilar Medicines Deliver More Savings Every Year

Video

Jan 5, 2022 | Erica Klinger

Join Us at Access! 2022 in Orlando, Florida!

AAM All Access Podcast

Jan 4, 2022 | Dan Leonard

AAM All Access Podcast: Bob Billings

Professional nurse does checkup of patient's intravenous and IV fluid bag

Dec 20, 2021 | Craig Burton

Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers

Ramprasad Reddy

Dec 14, 2021 | Bob Billings

Thank you, Ramprasad Reddy

Vial and syringe injection

Dec 3, 2021 | Craig Burton

The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations